Blue Rock Wealth Management LLC Purchases New Position in Pfizer Inc. $PFE

Blue Rock Wealth Management LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 12,709 shares of the biopharmaceutical company’s stock, valued at approximately $325,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Triumph Capital Management lifted its position in shares of Pfizer by 20.0% in the 4th quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 1,717 shares during the period. Gotham Asset Management LLC lifted its position in shares of Pfizer by 333.4% in the 4th quarter. Gotham Asset Management LLC now owns 141,040 shares of the biopharmaceutical company’s stock worth $3,742,000 after purchasing an additional 108,494 shares during the period. Finally, Janus Henderson Group PLC lifted its position in Pfizer by 80.7% during the 4th quarter. Janus Henderson Group PLC now owns 958,315 shares of the biopharmaceutical company’s stock valued at $25,434,000 after acquiring an additional 427,886 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.8%

NYSE PFE opened at $24.74 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market capitalization of $140.66 billion, a price-to-earnings ratio of 13.16, a price-to-earnings-growth ratio of 0.87 and a beta of 0.55. The company’s 50-day simple moving average is $24.85 and its two-hundred day simple moving average is $24.33. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the firm posted $0.60 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s payout ratio is presently 91.49%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PFE shares. HSBC reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research note on Monday, May 19th. Jefferies Financial Group boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, May 21st. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.